Avantor, Inc.
Financials
Valuation Metrics
Avantor, Inc.'s Market Cap is $10.83B. At end of 2025 it was $7.77B. Ranked #881 of 3,121 in US market (top 28%), #605 of 1,658 on NYSE (top 36%), #58 of 205 in Health Care Equipment & Services (top 28%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.83B | US#881/3,121 Sec#58/205 |
| Revenue | $6.56B | US#748/3,121 Sec#40/205 |
| Net Income | $-578M | US—/3,121 Sec—/205 |
| Total Assets | $11.60B | US#914/3,121 Sec#43/205 |
| Net Assets | $5.63B | US#645/3,121 Sec#38/205 |
| Employees | 13,500 | US#729/3,121 Sec#56/205 |
| Value | ||
| P/B | 1.92x | US#1,188/3,121 Sec#58/205 |
| P/S | 1.65x | US#1,117/3,121 Sec#76/205 |
| EV/EBITDA | 113.46x | US#2,447/3,121 Sec#137/205 |
| FCF Yield | 4.20% | US#1,584/3,121 Sec#83/205 |
| Profitability | ||
| ROE | -10.27% | US#2,374/3,121 Sec#136/205 |
| ROA | -4.98% | US#2,514/3,121 Sec#139/205 |
| Op. Margin | -4.35% | US#2,467/3,121 Sec#145/205 |
| Revenue Growth | -1.57% | US#2,346/3,121 Sec#172/205 |
| Earnings Growth | -184.09% | US#1,956/3,121 Sec#100/205 |
| Financial Health | ||
| Debt Ratio | 105.96% | US#1,152/3,121 Sec#107/205 |
| Total Debt | $3.70B | US#845/3,121 Sec#39/205 |
| FCF | $455M | US#938/3,121 Sec#51/205 |
| Cash | $307M | US#1,397/3,121 Sec#76/205 |
| Current Ratio | 1.78x | US#1,403/3,121 Sec#122/205 |
| Net Debt/EBITDA | 27.06x | US#2,492/3,121 Sec#143/205 |
| Performance | ||
| 1Y Return | 27.86% | US#962/3,121 Sec#75/205 |
| 1M Return | 18.94% | US#100/3,121 Sec#17/205 |
| From 52W High | -1.22% | US#64/3,121 Sec#12/205 |
| 1Y MDD | -52.50% | US#2,553/3,121 Sec#153/205 |
| Trading | ||
| Volume | 8,603,712 shares | US#175/3,121 Sec#5/205 |
| Trading Value | $136M | US#650/3,121 Sec#52/205 |
| Per Share | ||
| EPS | $-0.85 | US—/3,121 Sec—/205 |
| BPS | $8.25 | US#1,977/3,121 Sec#113/205 |
Company Info
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.